CA2380355A1 - Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci - Google Patents

Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci Download PDF

Info

Publication number
CA2380355A1
CA2380355A1 CA002380355A CA2380355A CA2380355A1 CA 2380355 A1 CA2380355 A1 CA 2380355A1 CA 002380355 A CA002380355 A CA 002380355A CA 2380355 A CA2380355 A CA 2380355A CA 2380355 A1 CA2380355 A1 CA 2380355A1
Authority
CA
Canada
Prior art keywords
seq
polypeptide
acid sequence
pro
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002380355A
Other languages
English (en)
Inventor
Dan L. Eaton
Ellen Filvaroff
Mary E. Gerritsen
Audrey Goddard
Paul J. Godowski
Christopher J. Grimaldi
Austin L. Gurney
Colin K. Watanabe
William I. Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1999/020111 external-priority patent/WO2000012708A2/fr
Priority claimed from PCT/US1999/021090 external-priority patent/WO2000015796A2/fr
Priority claimed from PCT/US2000/004341 external-priority patent/WO2000053756A2/fr
Priority claimed from PCT/US2000/004342 external-priority patent/WO2000078961A1/fr
Priority claimed from PCT/US2000/004414 external-priority patent/WO2001004311A1/fr
Priority claimed from PCT/US2000/005601 external-priority patent/WO2000056889A2/fr
Priority claimed from PCT/US2000/008439 external-priority patent/WO2000073454A1/fr
Priority claimed from PCT/US2000/014042 external-priority patent/WO2000077037A2/fr
Priority to CA002481691A priority Critical patent/CA2481691A1/fr
Priority to CA002481756A priority patent/CA2481756A1/fr
Priority to CA2481731A priority patent/CA2481731C/fr
Priority to CA002481788A priority patent/CA2481788A1/fr
Priority to CA002481685A priority patent/CA2481685A1/fr
Priority to CA002645727A priority patent/CA2645727A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2380355A1 publication Critical patent/CA2380355A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

L'invention concerne des nouveaux polypeptides et des molécules d'acides nucléiques codant pour lesdits polypeptides. L'invention porte également sur des vecteurs et des cellules hôtes comprenant lesdites séquences nucléotidiques, sur des molécules de polypeptides chimères comprenant les polypeptides de l'invention fusionnés à des séquences polypeptidiques hétérologues, sur des anticorps se liant aux polypeptides de l'invention et sur des procédés de production des polypeptides de l'invention.
CA002380355A 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci Abandoned CA2380355A1 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
CA002645727A CA2645727A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481685A CA2481685A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481788A CA2481788A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA2481731A CA2481731C (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481691A CA2481691A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481756A CA2481756A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci

Applications Claiming Priority (31)

Application Number Priority Date Filing Date Title
PCT/US1999/020111 WO2000012708A2 (fr) 1998-09-01 1999-09-01 Nouveaux pro-polypeptides et sequences correspondantes
USPCT/US99/20111 1999-09-01
PCT/US1999/021090 WO2000015796A2 (fr) 1998-09-16 1999-09-15 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US99/21090 1999-09-15
US16949599P 1999-12-07 1999-12-07
US60/169,495 1999-12-07
US17026299P 1999-12-09 1999-12-09
US60/170,262 1999-12-09
US17548100P 2000-01-11 2000-01-11
US60/175,481 2000-01-11
PCT/US2000/004342 WO2000078961A1 (fr) 1999-06-23 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US00/04341 2000-02-18
USPCT/US00/04342 2000-02-18
PCT/US2000/004341 WO2000053756A2 (fr) 1999-03-08 2000-02-18 Polypeptides secretes et transmembranaires et acides nucleiques codant ces polypeptides
PCT/US2000/004414 WO2001004311A1 (fr) 1999-07-07 2000-02-22 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ces polypeptides
USPCT/US00/04414 2000-02-22
PCT/US2000/005601 WO2000056889A2 (fr) 1999-03-23 2000-03-01 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
USPCT/US00/05601 2000-03-01
US18720200P 2000-03-03 2000-03-03
US60/187,202 2000-03-03
US19100700P 2000-03-21 2000-03-21
US60/191,007 2000-03-21
USPCT/US00/08439 2000-03-30
PCT/US2000/008439 WO2000073454A1 (fr) 1999-06-02 2000-03-30 Polypeptides transmembranaires secretes et acides nucleiques codants pour ceux-ci
US19939700P 2000-04-25 2000-04-25
US60/199,397 2000-04-25
PCT/US2000/014042 WO2000077037A2 (fr) 1999-06-15 2000-05-22 Polypeptides secretes et transmembranaires et acides nucleiques les codant
USPCT/US00/14042 2000-05-22
US20983200P 2000-06-05 2000-06-05
US60/209,832 2000-06-05
PCT/US2000/023328 WO2001016318A2 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci

Related Child Applications (6)

Application Number Title Priority Date Filing Date
CA002481756A Division CA2481756A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481691A Division CA2481691A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481685A Division CA2481685A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA2481731A Division CA2481731C (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002481788A Division CA2481788A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
CA002645727A Division CA2645727A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci

Publications (1)

Publication Number Publication Date
CA2380355A1 true CA2380355A1 (fr) 2001-03-08

Family

ID=40299613

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002380355A Abandoned CA2380355A1 (fr) 1999-09-01 2000-08-24 Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci

Country Status (5)

Country Link
EP (1) EP1208202A2 (fr)
JP (8) JP3951035B2 (fr)
AU (1) AU7573000A (fr)
CA (1) CA2380355A1 (fr)
WO (1) WO2001016318A2 (fr)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001066740A2 (fr) * 2000-03-03 2001-09-13 Genentech, Inc. Compositions et methodes de traitement de maladies d'origine immune
US7057017B2 (en) 1997-04-16 2006-06-06 Millennium Pharmaceuticals, Inc. Human dickkopf-related protein and nucleic acid molecules and uses therefor
US20030130182A1 (en) * 1997-11-05 2003-07-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6562578B1 (en) 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
JP3602442B2 (ja) 1998-01-09 2004-12-15 イミュネックス・コーポレーション ＩＬ−１δのＤＮＡおよびポリペプチド
US7446181B2 (en) 1998-01-15 2008-11-04 Millennium Pharmaceuticals, Inc. Antibodies that bind human Dickkopf-1 proteins
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US7771719B1 (en) 2000-01-11 2010-08-10 Genentech, Inc. Pharmaceutical compositions, kits, and therapeutic uses of antagonist antibodies to IL-17E
US7291712B2 (en) 1998-06-25 2007-11-06 Genentech, Inc. Interleukin-8 homologous polypeptides and therapeutic uses thereof
AU5447899A (en) * 1998-09-03 2000-03-27 Takeda Chemical Industries Ltd. Novel protein and process for producing the same
US7244817B2 (en) * 1998-09-10 2007-07-17 Genentech, Inc. Pro1357 polypeptide
US7244428B2 (en) * 1998-09-10 2007-07-17 Genentech, Inc. PRO1357 antibodies
US6344541B1 (en) 1998-09-25 2002-02-05 Amgen Inc. DKR polypeptides
AU2007216683B2 (en) * 1998-12-17 2011-07-14 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US6699664B1 (en) 1998-12-17 2004-03-02 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6962980B2 (en) 1999-09-24 2005-11-08 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US7888477B2 (en) 1998-12-17 2011-02-15 Corixa Corporation Ovarian cancer-associated antibodies and kits
US6858710B2 (en) 1998-12-17 2005-02-22 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6468546B1 (en) 1998-12-17 2002-10-22 Corixa Corporation Compositions and methods for therapy and diagnosis of ovarian cancer
US20030190669A1 (en) * 1998-12-30 2003-10-09 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6943235B1 (en) 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
DE60045201D1 (de) 1999-08-12 2010-12-16 Agensys Inc C-Typ-Lektin-Transmembran-Antigen, das in menschlichem Prostatakrebs exprimiert wird, und Verwendungen dieses Antigens
EP1219710B1 (fr) * 1999-09-29 2010-04-07 Teijin Limited Polypeptides et genes les codant
EP1235843A4 (fr) * 1999-10-29 2005-04-20 Human Genome Sciences Inc 26 proteines humaines secretees
CA2393369A1 (fr) 1999-12-03 2001-06-07 Zymogenetics, Inc. Recepteur de cytokine humaine
WO2001046419A2 (fr) * 1999-12-23 2001-06-28 Schering Corporation Proteines mammaliennnes, reactifs et procedes associes
US20030170823A1 (en) 1999-12-23 2003-09-11 Presnell Scott R. Novel cytokine ZCYTO18
US20040043397A1 (en) 2000-01-11 2004-03-04 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP1897944B1 (fr) * 1999-12-23 2011-08-10 Genentech, Inc. Polypeptides allogéniques IL-17 et utilisations thérapeutiques
MXPA02007119A (es) * 2000-01-19 2003-04-14 Amgen Inc Peptido relacionado a condromodulina-1.
WO2002000857A2 (fr) * 2000-06-15 2002-01-03 Millennium Pharmaceuticals, Inc. Acyltransférase humaine 53320 nouvellement découverte et ses utilisations
US7094566B2 (en) 2000-03-16 2006-08-22 Amgen Inc., IL-17 receptor like molecules and uses thereof
US7718397B2 (en) 2000-03-21 2010-05-18 Genentech, Inc. Nucleic acids encoding receptor for IL-17 homologous polypeptides and uses thereof
WO2001074854A2 (fr) * 2000-03-31 2001-10-11 Millennium Pharmaceuticals, Inc. Le 32449, nouveau transporteur humain et ses utilisations
GB0009907D0 (en) * 2000-04-20 2000-06-07 Smithkline Beecham Biolog Novel compounds
US20030096969A1 (en) 2000-06-02 2003-05-22 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA02012749A (es) * 2000-06-30 2003-10-06 Amgen Inc Moleculas semejantes a b7 y sus usos.
EP1736545A3 (fr) * 2000-08-08 2007-03-28 ZymoGenetics, Inc. Récepteurs de cytokines zcytor 11 solubles
EP2177616B1 (fr) * 2000-08-08 2012-02-29 ZymoGenetics, Inc. Récepteurs de cytokines zcytor 11 solubles
WO2002038764A2 (fr) * 2000-11-10 2002-05-16 The Regents Of The University Of California Proteine de type recepteur il-17, utilisation de celle-ci et modulation de l'activite catabolique des cytokines il-17 sur l'os et le cartilage
EP1873245A1 (fr) * 2001-02-28 2008-01-02 Genentech, Inc. Polypeptides homologue à l'interleukine-8 et utilisations thérapeutiques correspondantes
CA2439961A1 (fr) 2001-03-27 2002-10-03 Zymogenetics, Inc. Recepteur de cytokine humaine
US7033790B2 (en) 2001-04-03 2006-04-25 Curagen Corporation Proteins and nucleic acids encoding same
WO2005010044A2 (fr) 2003-07-08 2005-02-03 Genentech, Inc. Polypeptides heterologues il-17 a/f et utilisation des polypeptides a des fins therapeutiques
WO2003008589A1 (fr) * 2001-07-18 2003-01-30 Asahi Kasei Kabushiki Kaisha Elk1 gene associe a la phosphorylation
US20030018172A1 (en) * 2001-12-06 2003-01-23 Genentech, Inc. Secreted transmembrane polypeptides and nucleic acids encoding the same
EP1546358A4 (fr) 2002-03-22 2006-06-07 Zymogenetics Inc Anticorps anti-il-tif et leurs methodes d'utilisation dans une inflammation
EP2305710A3 (fr) 2002-06-03 2013-05-29 Genentech, Inc. Bibliothèques de phages et anticorps synthétiques
DE10254601A1 (de) * 2002-11-22 2004-06-03 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
JP2011516026A (ja) * 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド 免疫関連疾患の治療のための組成物と方法
US20040258696A1 (en) * 2003-02-05 2004-12-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7312197B2 (en) 2003-02-24 2007-12-25 University Of Maryland, Baltimore Method of modifying glucose activity using polypeptides selectively expressed in fat tissue
EP1606317B1 (fr) 2003-03-24 2010-07-28 ZymoGenetics, Inc. Anticorps anti-il-22ra et leurs partenaires de liaison, methodes d'utilisation de ces derniers dans les cas d'inflammation
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
EP3434275A1 (fr) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Méthode de dépistage de cellules cancéreuses basé sur l'utilisation de conjugués d'auristatin avec anticorps
AU2005213965B2 (en) * 2004-02-12 2009-11-19 Lexicon Pharmaceuticals, Inc. Gene disruptions, compositions and methods relating thereto
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
DE102004024617A1 (de) * 2004-05-18 2005-12-29 Ganymed Pharmaceuticals Ag Differentiell in Tumoren exprimierte Genprodukte und deren Verwendung
MXPA06014065A (es) 2004-06-01 2007-01-31 Genentech Inc Conjugados de droga-anticuerpo y metodos.
CA2574881C (fr) 2004-08-04 2013-01-08 Amgen Inc. Anticorps contre dkk-1
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
US20100111856A1 (en) 2004-09-23 2010-05-06 Herman Gill Zirconium-radiolabeled, cysteine engineered antibody conjugates
EA015706B1 (ru) 2004-10-22 2011-10-31 Займоджинетикс, Инк. Моноклональное антитело или его фрагмент, связывающиеся с полипептидом il-22ra, гуманизированное антитело, полученное из указанного антитела, гибридомы, продуцирующие антитело, и применение указанного антитела
EP1790664A1 (fr) 2005-11-24 2007-05-30 Ganymed Pharmaceuticals AG Anticorps monoclonaux contre claudin-18 pour le traitement du cancer
AU2006342792A1 (en) 2005-12-02 2007-11-08 Genentech, Inc. Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to IL-22 and IL-22R
US8058014B2 (en) 2006-09-29 2011-11-15 University Of Maryland, Baltimore Method of diagnosing or predicting disease states in a subject using omentin 1 and omentin 2
CA2721713C (fr) 2008-05-05 2019-07-09 Novimmune Sa Anticorps a reaction croisee anti-il-17a/il-17f et leurs procedes d'utilisation
EP2427203B1 (fr) 2009-05-05 2018-10-17 Novimmune S.A. Anticorps anti-il-17f et leurs utilisation
JP2013504585A (ja) 2009-09-09 2013-02-07 セントローズ， エルエルシー 細胞外標的化薬物複合体
WO2011130598A1 (fr) 2010-04-15 2011-10-20 Spirogen Limited Pyrrolobenzodiazépines et conjugués de celles-ci
SG185428A1 (en) 2010-06-08 2012-12-28 Genentech Inc Cysteine engineered antibodies and conjugates
WO2012074757A1 (fr) 2010-11-17 2012-06-07 Genentech, Inc. Conjugués d'anticorps alaninyl-maytansinol
US8679767B2 (en) 2011-05-12 2014-03-25 Genentech, Inc. Multiple reaction monitoring LC-MS/MS method to detect therapeutic antibodies in animal samples using framework signature peptides
PT2750713E (pt) 2011-10-14 2016-01-20 Genentech Inc Pirrolobenzodiazepinas e conjugados das mesmas
WO2013130093A1 (fr) 2012-03-02 2013-09-06 Genentech, Inc. Biomarqueurs pour un traitement à base de composés chimiothérapeutiques anti-tubuline
WO2013167153A1 (fr) 2012-05-09 2013-11-14 Ganymed Pharmaceuticals Ag Anticorps utiles dans le diagnostic du cancer
WO2013174404A1 (fr) 2012-05-23 2013-11-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
NZ707486A (en) 2012-10-12 2018-09-28 Adc Therapeutics Sa Pyrrolobenzodiazepine - anti-psma antibody conjugates
WO2014057120A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués anticorps - pyrrolobenzodiazépine
ES2738310T3 (es) 2012-10-12 2020-01-21 Medimmune Ltd Pirrolobenzodiazepinas y conjugados de las mismas
WO2014057114A1 (fr) 2012-10-12 2014-04-17 Adc Therapeutics Sàrl Conjugués pyrrolobenzodiazepine-anticorps anti-psma
US9931414B2 (en) 2012-10-12 2018-04-03 Medimmune Limited Pyrrolobenzodiazepine-antibody conjugates
ES2649990T3 (es) 2012-10-12 2018-01-16 Medimmune Limited Conjugados de anticuerpos anti-CD22-pirrolobenzodiazepinas
EP2906296B1 (fr) 2012-10-12 2018-03-21 ADC Therapeutics SA Conjugués anticorps - pyrrolobenzodiazépine
CN105073776B (zh) 2012-11-13 2019-04-12 拜恩科技股份公司 用于治疗表达紧密连接蛋白的癌症疾病的制剂
HK1216176A1 (zh) 2012-12-21 2016-10-21 Medlmmune Limited 用於治疗增殖性和自身免疫疾病的非对称吡咯并苯并二氮杂卓二聚物
BR112015014669B1 (pt) 2012-12-21 2023-09-26 Medimmune Limited Compostos pirrolobenzodiazepinas, conjugados compreendendo os mesmos e uso destes para tratar uma doença proliferativa
WO2014127785A1 (fr) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Polythérapie impliquant des anticorps dirigés contre la claudine 18,2 pour le traitement du cancer
CA2905181C (fr) 2013-03-13 2020-06-02 Medimmune Limited Pyrrolobenzodiazepines et ses conjugues servant a fournir une therapie ciblee
AU2014244245C1 (en) 2013-03-13 2018-04-19 Genentech, Inc. Pyrrolobenzodiazepines and conjugates thereof
CN105142674B (zh) 2013-03-13 2018-11-13 麦迪穆有限责任公司 吡咯并苯并二氮杂卓和其结合物
WO2014146672A1 (fr) 2013-03-18 2014-09-25 Ganymed Pharmaceuticals Ag Thérapie comprenant des anticorps dirigés contre cldn 18.2 pour le traitement du cancer
JP6993084B2 (ja) 2013-08-12 2022-02-03 ジェネンテック， インコーポレイテッド １－（クロロメチル）－２，３－ジヒドロ－１ｈ－ベンゾ［ｅ］インドール二量体抗体 － 薬物コンジュゲート化合物、並びに使用及び処置の方法
EP3054983B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépines
EP3054986B1 (fr) 2013-10-11 2019-03-20 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
GB201317982D0 (en) 2013-10-11 2013-11-27 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
EP3054985B1 (fr) 2013-10-11 2018-12-26 Medimmune Limited Conjugués anticorps-pyrrolobenzodiazépine
UA118113C2 (uk) 2013-12-16 2018-11-26 Дженентек, Інк. Пептидоміметичні сполуки та їх кон'югати антитіла з лікарським засобом
CA2928952A1 (fr) 2013-12-16 2015-06-25 Genentech, Inc. Composes peptidomimetiques et conjugues anticorps-medicament de ceux-ci
EP3082876B1 (fr) 2013-12-16 2018-01-17 Genentech, Inc. Composés conjugués anticorps-médicament dimérique à base de 1-(chlorométhyl)-2,3-dihydro-1 h-benzo [e]indole, et méthodes d'utilisation et de traitement
US10188746B2 (en) 2014-09-10 2019-01-29 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
TW201625688A (zh) 2014-09-12 2016-07-16 建南德克公司 經半胱胺酸改造之抗體及接合物
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
US10149913B2 (en) 2014-09-12 2018-12-11 Genentech, Inc. Anthracycline disulfide intermediates, antibody-drug conjugates and methods
JP2017533887A (ja) 2014-09-17 2017-11-16 ジェネンテック， インコーポレイテッド ピロロベンゾジアゼピン類及びその抗体ジスルフィドコンジュゲート
EP3223854A1 (fr) 2014-11-25 2017-10-04 ADC Therapeutics SA Conjugués anticorps-pyrrolobenzodiazépine
MX2017007169A (es) 2014-12-03 2018-05-02 Genentech Inc Compuestos de amina cuaternaria y conjugados de anticuerpofármaco de los mismos.
GB201506411D0 (en) 2015-04-15 2015-05-27 Bergenbio As Humanized anti-axl antibodies
GB201506402D0 (en) 2015-04-15 2015-05-27 Berkel Patricius H C Van And Howard Philip W Site-specific antibody-drug conjugates
KR102111338B1 (ko) 2015-10-02 2020-05-15 제넨테크, 인크. 피롤로벤조디아제핀 항체 약물 콘쥬게이트 및 이의 사용 방법
WO2017064675A1 (fr) 2015-10-16 2017-04-20 Genentech, Inc. Conjugués médicamenteux à pont disulfure encombré
EP3365025B1 (fr) 2015-10-20 2020-07-15 Genentech, Inc. Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US20170315132A1 (en) 2016-03-25 2017-11-02 Genentech, Inc. Multiplexed total antibody and antibody-conjugated drug quantification assay
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
CN118436801A (zh) 2016-05-20 2024-08-06 豪夫迈·罗氏有限公司 Protac抗体缀合物及其使用方法
JP7022080B2 (ja) 2016-05-27 2022-02-17 ジェネンテック， インコーポレイテッド 部位特異的抗体－薬物複合体の特徴付けのための生化学分析的方法
US10639378B2 (en) 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use
EP3496763B1 (fr) 2016-08-11 2026-04-01 Genentech, Inc. Prodrogues de pyrrolobenzodiazepines et leurs conjugués aux anticorps
EP3522933B1 (fr) 2016-10-05 2021-12-15 F. Hoffmann-La Roche AG Procédés de préparation de conjugués anticorps-médicament
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
US11160872B2 (en) 2017-02-08 2021-11-02 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
EP3612537B1 (fr) 2017-04-18 2022-07-13 Medimmune Limited Conjugués de pyrrolobenzodiazépine
CN110536703B (zh) 2017-04-20 2024-07-12 Adc治疗有限公司 使用抗axl抗体-药物缀合物的组合疗法
UA127900C2 (uk) 2017-06-14 2024-02-07 Ейдісі Терапьютікс Са Схема дозування для введення adc до cd19
RS62928B1 (sr) 2017-08-18 2022-03-31 Medimmune Ltd Konjugati pirolobenzodiazepina
US10301319B2 (en) 2017-09-20 2019-05-28 Ph Pharma Co., Ltd. Thailanstatin analogs
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
TW202037381A (zh) 2018-10-24 2020-10-16 瑞士商赫孚孟拉羅股份公司 綴合化學降解誘導劑及使用方法
EP3894427A1 (fr) 2018-12-10 2021-10-20 Genentech, Inc. Peptides de photoréticulation pour conjugaison spécifique de site à des protéines contenant fc
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
ES2967878T3 (es) 2019-03-15 2024-05-06 Medimmune Ltd Dímeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento del cáncer
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
CN117980327A (zh) 2021-11-03 2024-05-03 杭州多禧生物科技有限公司 抗体的特异性偶联
EP4637833A2 (fr) 2022-12-23 2025-10-29 Genentech, Inc. Conjugués d'agent de dégradation de céréblon et leurs utilisations
AU2024257248A1 (en) 2023-04-17 2025-11-06 Peak Bio, Inc. Antibodies and antibody-drug conjugates and methods of use and synthetic processes and intermediates
WO2026006688A2 (fr) 2024-06-28 2026-01-02 Firefly Bio, Inc. Conjugués d'anticorps de dégradation et leurs utilisations
WO2026006689A2 (fr) 2024-06-28 2026-01-02 Firefly Bio, Inc. Conjugués anticorps-dégradeur de bcl-xl et leurs utilisations

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707829A (en) * 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
EP1876241A3 (fr) * 1996-01-11 2008-07-30 Corixa Corporation Compositions et procédés pour le traitement et le diagnostic du cancer du sein
US5824504A (en) * 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
WO1999063088A2 (fr) * 1998-06-02 1999-12-09 Genentech, Inc. Proteines membranaires et acides nucleiques codant ces proteines
CA2308768A1 (fr) * 1997-11-07 1999-05-20 Human Genome Sciences, Inc. 125 proteines secretees humaines
JP2001523453A (ja) * 1997-11-13 2001-11-27 ジェンセット 分泌タンパク質の伸長ｃＤＮＡ
CA2322732A1 (fr) * 1998-03-11 1999-09-16 Edward R. Lavallie Proteines secretees et polynucleotides les codant
WO1999055865A1 (fr) * 1998-04-29 1999-11-04 Genesis Research And Development Corporation Limited Polynucleotides isoles de cellules de la peau et leurs procedes d'utilisation
AU3774300A (en) * 1999-06-02 2000-12-18 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same

Also Published As

Publication number Publication date
WO2001016318A2 (fr) 2001-03-08
EP1208202A2 (fr) 2002-05-29
JP3951035B2 (ja) 2007-08-01
JP2005245460A (ja) 2005-09-15
JP2005253469A (ja) 2005-09-22
JP2004507204A (ja) 2004-03-11
JP2005270107A (ja) 2005-10-06
JP2005224245A (ja) 2005-08-25
JP2009095345A (ja) 2009-05-07
JP2005253468A (ja) 2005-09-22
JP2005261437A (ja) 2005-09-29
AU7573000A (en) 2001-03-26
WO2001016318A3 (fr) 2001-11-29

Similar Documents

Publication Publication Date Title
US7189564B2 (en) PRO1335 nucleic acids
US7160985B2 (en) Pro180 polypeptide
WO2001016318A2 (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
US7189815B2 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7319008B2 (en) Nucleic acid underexpressed in melanoma
US7351543B2 (en) Antibodies to a polypeptide encoded by a nucleic acid underexpressed in melanoma
US20080286821A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7300758B2 (en) Nucleic acid underexpressed in esophageal tumor
CA2481731C (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
US20060160186A1 (en) Nucleic acid underexpressed in stomach tumor and lung tumor
US20050059102A1 (en) Secreted and transmembrane polypeptides and nucleic acids encoding the same
US7244817B2 (en) Pro1357 polypeptide
CA2645727A1 (fr) Polypeptides secretes et transmembranaires et acides nucleiques codant pour ceux-ci
US7288384B2 (en) Antibodies to polypeptides encoded by a nucleic acid underexpressed in esophageal tumor
US7423127B2 (en) Antibodies to a polypeptide encoded by a nucleic acid overexpressed in melanoma
EP1623991A2 (fr) Polypeptides sécrétés et transmembranaires ainsi que les acides nucléiques codant pour ceux-ci

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead